Health Tech Investment Strategies

The real opportunity in health tech isn’t another AI triage app or predictive tool. It’s addressing the 30 days after hospital discharge. Most venture-backed startups are going after the flashy areas: virtual primary care, AI radiology, and wearables. But any ER doc can tell you the avoidable spend is hiding in a boring place: what happens after a patient leaves the hospital. Where things break down: Discharge summaries don’t reach the next provider on time. Nursing facilities and home health agencies often still rely on fax or phone calls. Medication lists don’t match. The drugs prescribed at discharge often differ from what the pharmacy can supply, leading to dangerous gaps. Equipment and follow-up visits are delayed. Wound vacs, oxygen, or even the first nurse visit may not show up until days later. Breakthrough pain isn't addressed quickly, leading to unnecessary ER visits. No one “owns” the first 72 hours. Everyone assumes someone else is checking in, so problems get missed until the patient is back in the ER. If I were building, the minimum product would: Capture the discharge event in real time. Pull a simple feed from the hospital to know when a patient is going home. Run a quick risk screen. Flag high-risk patients (heart failure, COPD, sepsis, complex wounds) for extra attention. Trigger a short checklist: confirm meds are filled, equipment is delivered, and a nurse visit is scheduled within 48 hours. Send tasks directly into the systems that post-acute providers already use. No new portals, no duplicate data entry. Measure what happens. Did the first visit actually occur? Was the med list reconciled? Did the patient end up back in the ER within 7 or 30 days? How to prove it works (a 90-day pilot): Focus on two or three conditions with high readmission rates (e.g., heart failure, COPD). Track simple metrics: % of patients reached within 48 hours of discharge % with meds reconciled in 24 hours Readmissions within 7/14/30 days Cost savings for the payer vs. the historical baseline Why this is investable: Hospitals and payers already lose money on readmissions and preventable ED visits. Medicare and commercial plans reimburse for many of the activities (post-discharge check-ins, remote monitoring). A 10–20% reduction in readmissions in a targeted population is a meaningful ROI within months. What kills startups in this space: Relying on manual nurse calls without a real-time discharge feed (too slow). Creating portal instead of embedding into existing workflows. Selling only to hospitals (not scalable), without involving payers who control the economics. The durable wins will come from companies that can tie together hospitals, nursing facilities, home health, and pharmacies into one simple loop. Not flashy. But that’s why it’s wide open. #PhyCapPhyCap Fund #postacutecare #venture

Turns out the best investment opportunities in healthcare are hiding in nausea, gallstones, and constipation. In recent conversations with several large healthcare private equity funds, the consensus is clear: GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are not just transforming obesity care. They are quietly creating a secondary gold rush in treating the side effects of weight loss. And it is not small. More than 6 million Americans are already on GLP-1s. Global GLP-1 sales are expected to exceed 130 billion dollars annually by 2030. Up to 40 percent of patients experience significant gastrointestinal side effects. Around 5 to 7 percent end up with gallbladder complications. Sarcopenia is now a real concern. Mental health utilization among GLP-1 users is rising by nearly 20 percent. Fertility clinics are seeing double-digit growth from GLP-1-related cases. So while everyone is applauding the miracle of weight loss, the savviest investors are looking at the flip side. They are rolling up GI clinics, expanding ASC platforms with cholecystectomy capacity, funding digital fitness and nutrition programs to fight muscle loss, backing behavioral health services for body image and binge relapse, and building analytics tools to help payers track it all. It is not just a new drug. It is a new healthcare economy. I have unpacked this trend in detail in my latest white paper: a playbook for investing around the GLP-1 explosion by targeting the ripple effects no one is talking about. Because in healthcare, what goes down (appetite) must come up (utilization of something else). #PrivateEquity #Healthcare #GLP1 #OzempicEconomy #HealthTech #DigitalHealth #VentureCapital #ObesityCare #PEInvesting

Your HealthTech startup isn’t a tech company. Treating it like one can be fatal. I’ve watched brilliant founders from SaaS, fintech, and AI stumble in healthcare. Not because they lacked skill, but because they assumed healthcare works like every other industry. It doesn’t. Here’s what makes HealthTech a world of its own: 1. You’re selling to institutions, not individuals. Hospitals, insurers, and regulators move carefully, not quickly. Procurement in large systems can take 18+ months, with decisions driven by risk and compliance over hype. Committees replace single decision-makers, and the biggest competitor is often the status quo. 2. Trust is everything. In healthcare, one misstep - clinical, ethical, or regulatory - can destroy credibility overnight. I’ve seen startups lose traction after minor compliance lapses. The rules around AI and digital health evolve constantly, and staying ahead of regulation is now a core competency, not a checkbox. 3. Adoption is the hardest challenge. Clinicians spend roughly 40% of their day on admin tasks. Patients are already overloaded. If your product doesn’t fit seamlessly into existing workflows, it won’t get used... no matter how elegant the tech. True adoption takes empathy, support, and time. 4. Solve a mission-critical problem. In healthcare, survival depends on necessity, not novelty. “Nice-to-have” tools don’t last. Clinical validation through peer-reviewed studies and real-world evidence matters more than hype. Evidence earns trust—and trust drives growth. 5. Investors now expect proof of outcomes. Funding is shifting toward startups that demonstrate measurable clinical impact and sustainable revenue models, especially in high-need areas like maternal health and chronic disease management. Impact now trumps velocity. 6. Partnerships power growth. Strategic collaborations, like those between pharmaceutical companies and AI imaging startups, are shaping healthcare innovation. They help new entrants navigate regulation, gain credibility, and scale responsibly. 7. Play the long game. Healthcare rewards patience, resilience, and humility. Quick hacks and blitz-scaling don’t work here. The founders who listen, learn, and adapt to the system’s realities are the ones who thrive. HealthTech is healthcare. With just enough technology to make it work better, not worse. What would you add?

This Budget wasn’t really about health funding, but it did point to the future operating model of UK healthcare. And if you’re building in HealthTech, there are signals here you can’t ignore. 👇 1️⃣ Neighbourhood Health Centres → The new distribution layer for care Up to 250 new centres, 120 operating by 2030, funded through a redesigned PPP model. For founders, this matters because: • It decentralises care delivery • Creates new routes for integrated diagnostics, remote monitoring, and prevention • Shifts power from hospitals to neighbourhood-level infrastructure • Opens the door to value-based partnerships If you build solutions that rely on proximity, community-based workflows, population-level insights, or hybrid care models - this is your inflection point. 2️⃣ £300m NHS tech funding → A tiny uplift, but an enormous signal The real message isn’t the money it’s the focus - “Tech is the productivity lever.” Whether it’s: • automating admin • interoperable patient records • data infrastructure • workforce optimisation • or decision support This Budget doubles down on the idea that the NHS will hit targets only through smarter technology, not more headcount. For HealthTech founders, that means: • Clinical workflow tools are hot • AI + governance-ready data platforms are essential • Adoption curves will accelerate if your product integrates cleanly and reduces friction • The NHS is shifting from “nice-to-have innovation” to productivity-critical innovation 3️⃣Prevention got louder, and it’s a commercial opportunity The expanded soft drinks levy, vaping restrictions, the removal of the two-child limit, and gambling duty changes aren’t random public health tweaks. They’re the beginning of a prevention-first economic strategy. Founders building in: • metabolic health • obesity • cardiovascular risk • mental health • women’s health • children & adolescent health • behaviour change • community-based health models …should read this Budget as a clear mandate: prevention is officially a national priority, not a side project. 4️⃣ Social care silence → The biggest risk to system stability No new funding. Rising wage pressures. Shrinking workforce supply. If you’re building in ageing, homecare optimisation, workforce platforms or LTC management, the Budget reinforces one truth: care capacity is the existential bottleneck. Whoever solves this wins. 5️⃣ My Founder Take: ⬇️ The gap between ambition and funding is now a market opportunity⬇️ As someone who’s spent 15+ years building and scaling in HealthTech, this Budget reads like an invitation: “If you can help us work smarter, prevent earlier, and simplify the system - we need you.” And we should meet that challenge. #LinkedInNewsEurope

𝗛𝗼𝘄 𝘁𝗼 𝗔𝘁𝘁𝗿𝗮𝗰𝘁 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 𝘁𝗼 𝗬𝗼𝘂𝗿 𝗠𝗲𝗱𝗧𝗲𝗰𝗵 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 (Regulatory Strategy Secrets That Open Wallets 💵) Ever wondered why some MedTech startups secure funding while others struggle? 🤔 The difference often lies in how you position your regulatory strategy I've helped dozens of MedTech companies secure investment by getting their regulatory house in order. Here's what works: 𝗧𝗵𝗲 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝗠𝗶𝗻𝗱𝘀𝗲𝘁 Investors aren't just buying your technology they're buying your path to market. They need to see you've mapped the regulatory landscape before they'll open their chequebooks 𝗦𝘁𝗲𝗽 𝟭: 𝗖𝗿𝗮𝗳𝘁 𝗮 𝗥𝗼𝗯𝘂𝘀𝘁 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗗𝗼𝗰𝘂𝗺𝗲𝗻𝘁 👉 Include clear classification pathways (MDR/IVDR in EU, 510(k)/De Novo/PMA in US) 👉 Outline realistic timelines with contingencies 👉 Detail your regulatory budget with precision 𝗘𝘅𝗮𝗺𝗽𝗹𝗲: One client secured their next round of funder after we developed a regulatory strategy showing two parallel pathways, a primary MDR route and a contingency 510(k) approach with clear milestones for each 𝗦𝘁𝗲𝗽 𝟮: 𝗗𝗲𝗺𝗼𝗻𝘀𝘁𝗿𝗮𝘁𝗲 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗠𝗼𝗺𝗲𝗻𝘁𝘂𝗺 👉 Show evidence of pre-submission meetings with the FDA 👉 Highlight any lodged applications and/or with Notified Bodies/FDA/Competent Authorities 👉 Document positive feedback from regulatory consultations 𝗘𝘅𝗮𝗺𝗽𝗹𝗲: A Cambridge-based diagnostics company showcased their pre-submission meeting minutes with the MHRA, demonstrating regulator alignment on their novel technology approach. This evidence of regulatory momentum helped secure a £5M Series A. 𝗦𝘁𝗲𝗽 𝟯: 𝗕𝘂𝗶𝗹𝗱 𝗮 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗥𝗶𝘀𝗸 𝗠𝗶𝘁𝗶𝗴𝗮𝘁𝗶𝗼𝗻 𝗣𝗹𝗮𝗻 👉 Identify potential regulatory hurdles specific to your technology 👉 Develop mitigation strategies for each risk 👉 Create a "Plan B" for classification challenges 𝗘𝘅𝗮𝗺𝗽𝗹𝗲: A  startup anticipated classification ambiguity between Class IIa and Class IIb under EU MDR. We developed a dual submission plan, one targeting Class III with additional clinical data contingencies for Class III. This proactive approach reassured investors that regulatory setbacks wouldn’t derail commercialization Investors don’t just back new groundbreaking technology they back companies with a clear, risk mitigated path to market. If your regulatory strategy isn't watertight, you're leaving money on the table So, is your regulatory plan helping or hurting your fundraising efforts? #MedTech #Startups #RegulatoryStrategy #Funding #InvestorReady #MedicalDevices

I recently reviewed Barclays’ latest Global Hospital Capex Survey, and the outlook for 2026 is notably more optimistic and tech‑forward. Hospitals worldwide are planning accelerated capital investment, supported by improving procedure volumes, stronger revenue expectations, and greater stability across major markets. Here are the highlights shaping investment and what they mean for service teams and value‑based partnerships: What is driving investment in 2026? • Global hospital capex is expected to grow +6.2%, up from +4.3% last year • The US remains resilient, while China shows renewed upside as anti‑corruption impacts recede • Spending is increasingly focused on advanced imaging, workflow optimization, and high‑efficiency technologies Service insights: Where hospitals expect more from vendors One of the strongest themes in this year’s survey is the rising strategic importance of service and partnerships. Hospitals are not just buying equipment, they are seeking integrated, long‑horizon value. • Reliability, uptime, and total cost of ownership are becoming core decision drivers, reinforcing the importance of predictive service models and remote diagnostics • AI‑enabled service workflows are gaining traction, particularly in case prioritization, worklist management, and diagnostic support • Staffing shortages are pushing hospitals to prioritize workflow automation, training support, and efficiency‑boosting services • Value‑based partnerships are accelerating, with health systems looking for single‑vendor ecosystems that connect imaging, therapy, and informatics What this means for MedTech leaders as capital spending rebounds, differentiation is shifting beyond hardware: • Integrate clinical innovation with operational efficiency • Provide end‑to‑end service ecosystems • Reduce complexity for overwhelmed clinical teams • Demonstrate long‑term ROI through data‑driven service models   These shifts signal a fundamental change in how hospitals evaluate value. As capital investment accelerates, hospitals are becoming far more intentional about the partners they choose. In 2026, success will be defined by who can translate technology investment into operational resilience, clinical efficiency, and long‑term value. This is where long‑term partnership begins to outweigh transactional exchange.

Forget the headlines about tax cuts. The real story of the "One Big Beautiful Bill" for innovators is the radical redesign of the healthcare marketplace. This legislation just fired the starting gun on a new race in healthtech. The Rise of the Tech-Enabled DPC: The new HSA flexibility for Direct Primary Care isn't just a tweak; it's a launchpad. The next billion-dollar healthtech opportunities may lie in building the operating systems for independent, patient-focused primary care practices. Rural Health is Now a Tech Frontier: $50 billion is earmarked to bring advanced technology to rural America. This is a direct challenge to innovators: Can you build the rugged, scalable, AI-powered tools that solve for care access and quality where it's needed most? The Double-Edged Sword for AI: The bill restores full R&D expensing, fueling investment. Yet, the failure to standardize AI regulation creates a compliance nightmare. This forces a critical strategic choice: innovate cautiously, or build for a future of regulatory complexity? The tectonic plates of healthcare have shifted. We're facing a changed payer mix, new incentives in primary care, and a clear (if challenging) path for technology adoption. The companies that thrive will be those that don't just adapt to these rules but build the very future they enable. What are you building? #HealthcareInnovation #HealthTech #DigitalHealth #AI #PrimaryCare #DPC #RuralHealth #HealthcareInvesting #FutureofHealth

I’ve watched too many promising health tech companies hit $10-15M in revenue and then just… stall. Great product, solid clinical data, enthusiastic early customers. But they can’t break through to real scale. The pattern is remarkably consistent across different technologies and therapeutic areas. And the culprit is almost always the same: they’ve been building toward the wrong milestone. The real gate isn’t product-market fit or some arbitrary quality metric. It’s a coverage determination from CMS. Here’s what most founders miss: CMS coverage decisions aren’t just about reimbursement. They’re market validation mechanisms that cascade across commercial payers, venture capital, physician adoption, and even competitor roadmaps. When CMS signals that a technology merits serious consideration, it validates the underlying clinical and economic premise in ways that no amount of VC funding or commercial success can replicate. The challenge is brutal. You need robust clinical evidence to get coverage. But you need coverage to generate the revenue that funds evidence generation. It’s a vicious circle that has destroyed many promising companies. The companies that scale successfully treat CMS engagement as a market creation tool from day one, not a post-commercialization afterthought. They reverse engineer their entire development strategy around the coverage pathway. They engage with CMS years before submitting formal requests. They design trials that serve both regulatory and reimbursement objectives simultaneously. For founders targeting Medicare populations, your coverage strategy should be as central to your business plan as product development. This means being realistic about timelines and capital requirements. The path from FDA clearance to meaningful revenue is longer and more expensive than most entrepreneurs anticipate. I wrote a longer piece exploring the mechanics of coverage determinations, the reimbursement chasm that traps early-stage companies, and specific strategic principles for founders navigating these dynamics. If you’re building in health tech or investing in the space, understanding this architecture isn’t optional anymore. ----- Disclaimer: These thoughts and opinions are my own and do not reflect the views of my employer or any other entities. ----- Link to the full analysis in the comments below.

Over the last 6 months, I’ve met with 100+ startup founders, attended 13 pitch competitions, and reviewed 60+ pitch decks. Here are the biggest mistakes I’ve seen BioTech/HealthTech startups make, and how to avoid them. 1. Neglecting regulatory strategy ⚖️ Investors want to see a well-mapped regulatory strategy that addresses IND, 510(k), or PMA processes, including contingency plans for handling FDA feedback and key milestones for clinical trial phases. If you claim you can obtain an FDA breakthrough designation, you better have a solid case... 2. Weak differentiation ⚔️ I cannot stress that enough: “We’re the first to do X” is NOT a moat. 3. Underestimating clinical trial costs 💸 Too often, startups don’t account for the true cost of clinical trials. Partnering with a large CRO may seem attractive but can be 10x more expensive than a smaller, boutique CRO (!). Understand your options and choose wisely. 4. Overestimating market size without addressing reimbursement 🏥 It’s not enough to estimate a billion-dollar TAM. Reimbursement is what drives adoption in BioTech/HealthTech. Demonstrate a thorough understanding of the reimbursement landscape, including CPT codes, payer coverage, and market access barriers. 5. Insufficient data to support claims 📊 “Promising results” from a small sample won't impress VCs. Present comprehensive datasets, validated biomarkers, and statistically significant findings. 6. Weak IP strategy 🔏 A single provisional patent is NOT enough. Investors expect FTO analyses, a robust patent portfolio, and strategies for secondary patents to fortify your IP. 7. Misjudging payer incentives and HTA requirements 🏛️ Don’t just mention pursuing Medicare coverage under NCD/LCD. Your reimbursement strategy should address HTAs, regional variations, and the implications of value-based care models like MACRA and MIPS. 8. Overemphasis on preclinical data without IND-enabling studies 🧪 Promising efficacy in animal models is great, but investors need to see a clear line of sight to the clinic. Ensure IND-enabling studies, including GLP toxicology and safety pharmacology, are complete and address any immunogenicity concerns upfront. 9. Overly complex language 🧠 This one should be obvious, yet it’s a common issue: if your pitch requires a PhD to understand, it’s not investor-ready! 10. Neglecting companion diagnostics and biomarker strategies in precision medicine 🧬 If you’re developing a targeted therapy, integrate companion diagnostics early. Outline co-development strategies with CLIA/CAP-accredited labs and validate predictive biomarkers that correlate with clinical outcomes. Which mistakes do you see most often in BioTech/HealthTech startups? Share them in the comments 👇